HSINCHU, July 31,
2024 /PRNewswire/ -- JelloX Biotech Inc.
('JelloX') is pleased to announce that it has entered into a
collaboration through a know-how agreement with Mayo Clinic to
further develop and validate their 3D digital imaging and AI
analysis technology. JelloX previously participated in the fifth
cohort of the Mayo Clinic and Arizona State
University Alliance for Health Care MedTech
Accelerator, a flagship program providing early-stage medical
device and healthcare technology companies with curriculum to
accelerate their go-to-market plans. JelloX has developed a 3D
pathology imaging technology with artificial intelligence (AI) for
spatial analysis to support precision cancer diagnosis.
![(PRNewsfoto/JelloX Biotech) (PRNewsfoto/JelloX Biotech)](https://mma.prnewswire.com/media/1939619/X_Logo.jpg)
Cancer diagnosis using traditional 2D imaging methods can miss
spatial relationships of critical tumor biomarkers and suffer
from interpretive variability. JelloX's 3D imaging technology
captures enhanced spatial context, providing a 3D view of tissue
architecture that hopes to improve diagnostic accuracy and
consistency and provide pathologists a more comprehensive diagnosis
for cancer patients. Furthermore, the same biopsy tissue can then
be analyzed by genomic sequencing and proteomics to provide
patients with the full spectrum of precision medicine.
JelloX's CEO and founder, Dr. Yen-Yin
Lin added, "Working with Mayo Clinic through this
know-how collaboration and MedTech Accelerator has been an
incredible journey for us. We are excited to bring our 3D pathology
technology to research and clinical practice. Our goal is to
provide researchers and clinicians with more precise diagnostic
tools and to support pharmaceutical companies in their quest to
develop new drugs to match patients with the right treatment at the
right time."
The collaboration is an example of how innovation and
collaboration can collectively advance opportunities to improve
healthcare outcomes for patients. As the field of pathology
continues to evolve, the integration of digital solutions like
JelloX's 3D pathology could contribute to the future of medical
diagnostics and treatment.
Mayo Clinic has a financial interest in the technology
referenced in this press release. Mayo Clinic will use any
revenue it receives to support its not-for-profit mission
in patient care, education and research.
About JelloX
JelloX, is at the forefront of innovation in the pathology space.
Its patented 3D digital pathology tissue imaging with AI-empowered
analysis translates into a precision diagnosis solution. The aim is
to create the world's first 3D digital pathology solution
in support of precision cancer diagnosis, optimize patient
treatment outcome, and match the right patients with the right
drugs at the right time. For more information, visit [JelloX
Website].
CONTACT:
JelloX Biotech Inc.
https://jellox.com/
Tel: +886-3-6583058
Fax: +886-3-5620853
Email: sales@jellox.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jellox-biotech-collaborates-with-mayo-clinic-to-develop-ai-enhanced-3d-pathology-imaging-technology-302210897.html
SOURCE JelloX Biotech Inc.